Duke Cancer Institute ( Site 2005)

Durham, North Carolina 27710

0 studies enrolling now · 1 studies all time

What they study most

Melanoma

Studies at this site

• Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02) — Completed